Argos Therapeutics to Report Third Quarter 2017 Financial Results and Operational Highlights on Thursday, November 9, 2017
November 06 2017 - 10:04AM
Argos Therapeutics Inc. (NASDAQ:ARGS), an immuno-oncology company
focused on the development and commercialization of individualized
immunotherapies based on the Arcelis® precision immunotherapy
technology platform, today announced that the Company will report
third quarter 2017 financial results and operational highlights
after the market closes on Thursday, November 9, 2017. Argos
executive management will host a conference call beginning at 4:30
p.m. Eastern Time to discuss these results and to provide an update
on immunology data from the Phase 3 ADAPT clinical trial to be
presented at the 32nd Annual Meeting of the Society for
Immunotherapy of Cancer to be held November 8 – 12 in National
Harbor, Maryland.
To participate by telephone, please dial (855)
433-0930 (Domestic) or (484) 756-4271 (International). The
conference ID number is 9396519. A live and archived audio webcast
can be accessed through the Investors section of the Company's
website at www.argostherapeutics.com. The archived webcast will
remain available on the Company's website for twelve (12) months
following the call.
About Argos Therapeutics
Argos Therapeutics is an immuno-oncology company
focused on the development and commercialization of individualized
immunotherapies for the treatment of cancer and infectious diseases
using its Arcelis® technology platform. Argos' most advanced
product candidate, Rocapuldencel-T, is being evaluated in the
pivotal ADAPT Phase 3 clinical trial for the treatment of
metastatic renal cell carcinoma (mRCC). Argos is also developing a
separate Arcelis®-based product candidate, AGS-004, for the
treatment of human immunodeficiency virus (HIV), which is currently
being evaluated in combination with vorinostat, a latency-reversing
drug, in an investigator-initiated Phase 2 clinical trial aimed at
HIV eradication in adult patients. Funding for the development of
AGS-004 has been provided by the National Institutes of Health, the
National Institute of Allergy and Infectious Diseases, and the
Collaboratory of Research for AIDS Eradication.
Forward Looking Statements
Any statements in this press release about
Argos' future expectations, plans and prospects, and other
statements containing the words "believes," "anticipates,"
"estimates," "expects," "intends," "plans," "predicts," "projects,"
"targets," "may," "potential," "will," "would," "could," "should,"
"continue," and similar expressions, constitute forward-looking
statements within the meaning of The Private Securities Litigation
Reform Act of 1995. Actual results may differ materially from
those indicated by such forward-looking statements as a result of
various important factors, including whether Argos' cash resources
will be sufficient to fund its continuing operations for the period
anticipated; whether preliminary or interim clinical data will be
indicative of the final data from a clinical trial; whether results
obtained in clinical trials will be indicative of results obtained
in future clinical trials; whether Argos' product candidates will
advance through the clinical trial process on a timely basis;
whether the results of such trials will warrant submission for
approval from the United States Food and Drug Administration or
equivalent foreign regulatory agencies; whether Argos' product
candidates will receive approval from regulatory agencies on a
timely basis or at all; whether, if product candidates obtain
approval, they will be successfully distributed and marketed;
whether Argos can successfully establish commercial manufacturing
operations on a timely basis or at all; and other factors discussed
in the "Risk Factors" section of Argos' Form 10-Q for the quarter
ended June 30, 2017, which is on file with the SEC, and in other
filings Argos makes with the SEC from time to time. In addition,
the forward-looking statements included in this press release
represent Argos' views as of the date hereof. Argos anticipates
that subsequent events and developments will cause Argos' views to
change. However, while Argos may elect to update these
forward-looking statements at some point in the future, Argos
specifically disclaims any obligation to do so. These
forward-looking statements should not be relied upon as
representing Argos' views as of any date subsequent to the date
hereof.
Investor contact: Richard Katz, MD, MBAChief
Financial Officer Argos Therapeutics, Inc. 919-287-6315
rkatz@argostherapeutics.com
Media Contact:Adam DaleyBerry & Company
Public Relations212.253.8881adaley@berrypr.com